Clinical trials: Ovarian Cancers
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
In April 2017, Tesaro, Inc. opened an expanded access program (EAP) to make niraparib, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor, available to eligible women with recurrent epithelial ovarian, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04546373
- Testing
- Niraparib
- Where
- 57 sites in Spain
- Volunteers
- 316 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Ovarian Cancer
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
This is a prospective, interventional, single-arm, open-label, phase II study to evaluate the safety and efficacy of niraparib monotherapy as neoadjuvant therapy in patients with advanced ovarian cancer, primary peritoneal…
- Trial name
- NCT04507841
- Testing
- Niraparib
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Tongji Hospital
Ovarian Cancer
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer.
- Trial name
- RegeNovar (NCT07637851)
- Testing
- Ubamatamab, Chemotherapy, Bevacizumab
- Where
- 11 sites in France
- Volunteers
- 43 people
- Sponsor
- ARCAGY/ GINECO GROUP
Polycystic Ovarian Syndrome, Obesity
Post-Prandial Liver Glucose Metabolism in PCOS
The Investigators will measure if hepatic metabolism is upregulated in obese girls with PCOS and hepatic steatosis (HS), compared to PCOS without HS and obese controls without HS.
- Conditions
- Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
- Trial name
- PLUM (NCT03041129)
- Testing
- oral glucose tolerance test, MRI of liver
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Polycystic Ovary Syndrome
OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women
Objective: To assess effectiveness of ISD (Insulin sensitizing drugs) Vs OCP (Combined E\&P cyproterone acetate) in improving clinical, hormonal and metabolic features of PCOS( polycystic ovary syndrome)women from India.
- Trial name
- OCP (NCT02744131)
- Testing
- Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate, Metformin 1500mgs per day
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Kar Clinic & Hospital Pvt. Ltd.
Polycystic Ovary Syndrome (PCOS), Overweight
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
Polycystic ovary syndrome (PCOS) is a health problem that affects one in 10 women of childbearing age, which is usually characterized by hormonal imbalance and metabolism problems such as hyperandrogenism and obesity.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Overweight, Obesity
- Trial name
- NCT03151005
- Testing
- Metformin-GLP-1 Receptor Agonist, Metformin-Oral Contraceptive(OC)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Xinqiao Hospital of Chongqing
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- NCT01233505
- Testing
- veliparib, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
The Effectiveness of an Online Support Group in Enhancing Recovery Identity and Health-Related Quality of Life
Background Ovarian cancer poses challenges for middle-aged and older patients, impacting physical and self-conceptual aspects. A research gap exists on the impact of online support groups (SPs) on identity synthesis and…
- Trial name
- NCT06145295
- Testing
- mobile online support group (experiment group), offline support group (control group)
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Ovarian Cancer
Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer
An anticipated 200 women with newly diagnosed ovarian and endometrial cancer scheduled to receive chemotherapy (adjuvant chemotherapy after surgery or neoadjuvant chemotherapy before surgery) will be recruited from Smilow Cancer…
- Trial name
- TEAL (NCT05761561)
- Testing
- Exercise and medical nutrition
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Yale University
Ovarian Cancer, Adnexal Mass
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.
- Trial name
- NCT04051502
- Testing
- Method 1: Indocyanine green dye, Method 2: Indocyanine green dye, Method 3: Indocyanine green dye
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Polycystic Ovary Syndrome, Obesity
Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in reproductive age women. PCOS is usually characterized by an excessive androgen production, menstrual irregularities, and polycystic ovaries.
- Trial name
- OMgObPCOS (NCT02521753)
- Testing
- Metformin, Magnesium, PUFA
- Where
- Mexico
- Volunteers
- 123 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Recurrent Ovarian Carcinoma
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
This is a phase III, randomized, partially blinded, multicenter trial to evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared to placebo plus bevacizumab and chemotherapy in patients with…
- Trial name
- NCT03353831
- Testing
- Bevacizumab, Atezolizumab, Chemotherapy
- Where
- 111 sites in Austria, Belgium and 10 more
- Volunteers
- 574 people
- Sponsor
- AGO Research GmbH
Advanced Solid Tumor
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091)…
- Trial name
- NCT05932862
- Testing
- XL309, Olaparib
- Where
- 16 sites in United States
- Volunteers
- 429 people
- Sponsor
- Exelixis
Ovarian Cancer
Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer
The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after…
- Trial name
- NCT02132988
- Testing
- OPT-822/OPT-821
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- Mackay Memorial Hospital
Treatment Related Cancer, Diagnoses Disease
Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017
This study is a population-based, patient-level analysis of colon and ovarian cancer diagnoses in England over a 2-year period using a dataset created by linking NCRAS and NHS digital datasets.
- Conditions
- Treatment Related Cancer, Diagnoses Disease, Equality, Gender
- Trial name
- NCT05185388
- Where
- United Kingdom
- Volunteers
- 45,831 people
- Sponsor
- University of Hull
Cholelithiases, Appendicitis
Effect of Intravenous Lignocaine Infusion on Intraoperative End Tidal Desflurane Concentration Requirements
Lignocaine is a local anaesthetic that is widely used in all medical and surgical fields. Many clinical studies have shown that intravenous (IV) lignocaine given in the perioperative period was safe, reduced airway complications…
- Conditions
- Cholelithiases, Appendicitis, Ovarian Cysts
- Trial name
- NCT06064331
- Testing
- Lignocaine
- Where
- Malaysia
- Volunteers
- 48 people
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002894
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Medical Research Council
Ovarian Cancer, Fallopian Tube Cancer
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Patients who have this kind of cancer are often treated with several drugs. Carboplatin is one that seems to work for many treatment cycles. Even though it may work against the cancer, the patient can become allergic to it.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01248962
- Testing
- carboplatin
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Quality of Life
Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00004166
- Testing
- amifostine trihydrate, quality-of-life assessment
- Where
- United States
- Sponsor
- Northwestern University
Platinum-sensitive Ovarian Cancer (UPGRADE-A)
Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
Phase 1 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in combination with Carboplatin in participants with high-grade serous…
- Trial name
- UPGRADE (NCT04907968)
- Testing
- XMT-1536 (Upifitamab Rilsodotin), Carboplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Mersana Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.